Living with multiple sclerosis (MS) could be compared to having an annoying house guest that never leaves. At first you can tolerate them, but soon your nerves and resilience wear thin.
You try to accept and adapt to the house guest, but you never give up on trying to get them to pack up and move on.
Evgen Pharma (LON:EVG) is a clinical stage drug development company whose lead programmes are in breast cancer and subarachnoid haemorrhage, a type of stroke. The company is carrying out preclinical work in multiple sclerosis and has a clinical interest in prostate cancer. Evgen Pharma’s objective is to become the leading company in the development of pharmaceuticals that activate the antioxidant response element, Nrf2.